摘要
肽谱分(VeriStrat)是一种基于血液蛋白质组学试验,用于非小细胞肺癌(non-small cell lung cancer,NSCLC)患者用药效果的预测性和预后性分类测试方法。该测试时患者被分类为VeriStrat-Good组和Veri Strat-Poor组,通过表征宿主对肿瘤的反应来评估疾病的侵袭性,还可用于NSCLC的精准医学诊断。我们对VeriStrat在临床的应用现状进行阐述,并分析探讨VeriStrat在NSCLC及其他肿瘤个体化治疗中的临床价值,以推动肿瘤个体化治疗的进步。
The VeriStrat test is a blood-based proteomic test with predictive and prognostic significance in treatment of non-small cell lung cancer(NSCLC).Mass spectra from these patients′serum samples were classified into two outcome groups,VeriStrat-Good group and VeriStrat-Poor group which are used to evaluate different treatment outcomes.It also cam used for precision medicime of NSCLC.Our paper illustrates the current progress in the clinical application of VeriStrat test,and aims to investigate the clinical value of Veristrat test in the treatment of NSCLC and other tumors.In summary,VeriStrat test is helpful to promote the application of individualized treatments.
作者
陈锋
张荣
刘昕超
崔松
杨珺
马庆伟
陈琛
张晓青
崔巍
Chen Feng;Zhang Rong;Liu Xinchao;Cui Song;Yang Jun;Ma Qingwei;Chen Chen;Zhang Xiaoqing;Cui Wei(National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Buoying Technologies Inc, Beijing 102206, China)
出处
《中华临床实验室管理电子杂志》
2017年第4期217-220,共4页
Chinese Journal of Clinical Laboratory Management(Electronic Edition）
基金
中国医学科学院医学与健康科技创新工程项目(2017-12M-3-005)
关键词
非小细胞肺癌
个体化治疗
肿瘤
肽谱分
Non-small cell lung cancer
Individualized treatment
Tumors
VeriStrat
